CytomX Therapeutics Announces Presentations at the 2020 American Society of Clinical Oncology Virtual Scientific Program
2020年4月30日 - 5:05AM
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage
oncology-focused biopharmaceutical company pioneering a novel class
of investigational antibody therapeutics based on its Probody®
therapeutic technology platform, today announced the selection of
seven presentations to be featured as part of the American Society
of Clinical Oncology’s (ASCO) ASCO20 Virtual Scientific Program
taking place from May 29 - May 31, 2020.
The titles of the abstracts are currently available on ASCO’s
2020 Digital Scientific Program, with full abstracts, including the
dates and times of presentations, scheduled for publication on May
13, 2020.
A list of accepted abstracts by CytomX and its partners is
provided below.
ASCO 2020 Clinical Highlights From Across the CytomX
Probody Portfolio
- Preliminary Data from Phase 1/2 Trial of CX-2029, a CD71
Targeting Probody Drug Conjugate, Partnered with AbbVie
- Preliminary Phase 1 Clinical Data Presented by Bristol Myers
Squibb from the Ongoing First-in-Human Phase 1/2a trial of
BMS-986249, a Probody Version of the anti-CTLA-4 Antibody
ipilimumab
- Updated Data from the Phase 1/2 Trial of CX-2009, an Anti-CD166
Probody Drug Conjugate
- Updated Clinical Data from the Phase 1/2 Trial of CX-072, an
Anti-PD-L1 Probody Therapeutic, as Monotherapy, in Selected Tumor
Types and in Combination with ipilimumab
“Our presence at ASCO this year highlights the strong clinical
progress made by CytomX and our partners in exploring the broad
potential of the novel Probody technology platform,” said Amy
Peterson, M.D., chief development officer of CytomX Therapeutics.
“We look forward to updating the oncology community on this
progress and on next steps towards our vision of transforming the
lives of patients with cancer.”
CX-2029, An Anti-CD71 Probody Drug
Conjugate
Presentation Title: CX-2029, a PROBODY Drug
Conjugate Targeting CD71 (Transferrin Receptor): Results from a
First-in-Human Study (PROCLAIM-CX-2029) in Patients (Pts) With
Advanced Cancer Session Title: Developmental
Therapeutics—ImmunotherapyAbstract: 3502
Session Type: Oral Presentation
CX-072, An Anti-PD-L1 Probody Therapeutic
Presentation Title: PROCLAIM-CX-072: Analysis
of Patients With Advanced Solid Tumors Receiving Long-Term
Treatment With CX-072, a PD-L1 PROBODY Therapeutic, as a Single
Agent or in Combination With Ipilimumab. Session
Title: Developmental Therapeutics—Immunotherapy
Abstract: 2005 Session Type: Oral
Presentation Presentation Title: Evidence of
Intratumoral Localization, Activation, and Immunomodulatory Effect
of CX-072, a PROBODY Therapeutic Targeting PD-L1, in a Phase 1/2
Trial Session Title: Developmental
Therapeutics—Immunotherapy Abstract: 3108
Session Type: Poster Presentation (Poster #172)
Presentation Title: Preliminary Population
Pharmacokinetics Supports Phase 2 Dose Selection for Masked
Anti–PD-L1 Antibody CX-072 Session Title:
Developmental Therapeutics—Immunotherapy Abstract:
3602 Session Type: Poster Presentation (Poster
#332)
CX-2009, An Anti-CD166 Probody Drug
Conjugate
Presentation Title: CX-2009, A CD166-Directed
PROBODY Drug Conjugate (PDC): Results From the First-in-Human Study
in Patients With Advanced Cancer Including Breast Cancer
Session Title: Developmental
Therapeutics—Immunotherapy Abstract: 526
Session Type: Poster Presentation (Poster #18)
Presentation Title: Preliminary Clinical
Pharmacokinetics and Dose-Response to Support a Phase 2 Dose
Selection for CX-2009: A Masked PROBODY Drug Conjugate to CD166
Session Title: Developmental
Therapeutics—Immunotherapy Abstract: 3599
Session Type: Poster Presentation (Poster
#329)
BMS-986249, An Anti-CTLA-4 Probody
Therapeutic
Presentation Title: Anti–CTLA-4 probody
BMS-986249 Alone or in Combination with Nivolumab in Patients with
Advanced Cancers: Initial Phase 1 Results Session
Title: Developmental Therapeutics—Immunotherapy
Abstract: 3058 Session Type:
Poster Presentation (Poster #122)
About CytomX Therapeutics CytomX is a
clinical-stage, oncology-focused biopharmaceutical company with a
vision of transforming lives with safer, more effective therapies.
We are developing a novel class of investigational antibody
therapeutics, based on our Probody® technology platform, for
the treatment of cancer. Probody therapeutics are designed to
remain inactive until they are activated by proteases in the tumor
microenvironment. As a result, Probody therapeutics are intended to
bind selectively to tumors and decrease binding to healthy tissue,
to minimize toxicity and potentially create safer, more effective
therapies. As leaders in the field, our innovative technology is
designed to turn previously undruggable targets into druggable
targets and to enable more effective combination therapies. CytomX
and its partners, comprised of leading biotechnology and
pharmaceutical companies, have developed a robust pipeline of
potential first-in-class therapeutic candidates against novel,
difficult to drug targets and potential best-in-class
immunotherapeutic candidates against clinically validated targets.
The CytomX clinical stage pipeline includes first-in-class product
candidates against previously undruggable targets, including a
CD166-targeting Probody drug conjugate wholly owned by CytomX
(CX-2009) and a CD71-targeting Probody drug conjugate partnered
with AbbVie (CX-2029). CD166 and CD71 are among cancer targets that
are considered to be inaccessible to conventional antibody drug
conjugates due to their presence on many healthy tissues. The
CytomX clinical stage pipeline also includes cancer
immunotherapeutic candidates against validated targets such as the
CTLA-4-targeting Probody therapeutics, BMS-986249 and BMS-986288,
partnered with Bristol Myers Squibb. CytomX has strategic drug
discovery and development collaborations with AbbVie, Amgen,
Astellas and Bristol Myers Squibb. For additional information
about CytomX Therapeutics,
visit www.cytomx.com and follow us
on LinkedIn and Twitter.
Probody is a U.S. registered trademark of CytomX
Therapeutics, Inc. Investor and Media Contact:
Christopher Keenan VP, Investor Relations and Corporate
Communications ckeenan@cytomx.com 650-383-0823
CytomX Therapeutics (NASDAQ:CTMX)
過去 株価チャート
から 6 2024 まで 7 2024
CytomX Therapeutics (NASDAQ:CTMX)
過去 株価チャート
から 7 2023 まで 7 2024